Brief: Kubota Pharmaceutical Holdings unit gets orphan drug designation from FDA for treatment of stargardt disease

Kubota Pharmaceutical Holdings

06/01/2017 06:26

Jan 6 (Reuters) - Kubota Pharmaceutical Holdings Co Ltd 
 4596.T : 
     
    * Says its unit Acucela Inc announced that the FDA (U.S. 
Food and Drug Administration) granted orphan drug designation to 
Acucela's leading drug candidate emixustat 
hydrochloride("emixustat") for the treatment of stargardt 
disease 
     
     
    Source text in Japanese: https://goo.gl/jLgyqA 
    Further company Coverage:  4596.T  
 
 (Beijing Headline News) 
 ((Beijing.HeadlineNews@thomsonreuters.com; +86 010 62674724; 
Reuters Messaging: qiujing.li.thomsonreuters.com@reuters.net))